Free Newsletter
Sweep the FDA clean, Stupak says
Rep. Bart Stupak, the influential Michigan Democrat known so well to pharma, is lobbying President-elect Barack Obama for a wholesale change in FDA leadership. A frequent critic of the agency, Stupak maintains in a letter to Obama that the FDA's top officials are "too close with the industries they regulate." He wants the president-elect to sweep the ranks clean with a "complete change" in management.
The letter appears to be a response, at least in part, to some Democratic support for CDER chief Janet Woodcock as an interim FDA commissioner. Industry types are also backing Woodcock as either interim or permanent FDA chief, the Wall Street Journal reports.
As you know, the FDA has been criticized from all sides over the past couple of years, as withdrawals of popular meds (such as Vioxx)and safety recalls (such as this year's heparin debacle) tarnished the agency's reputation. Few now argue that the FDA doesn't need widespread reform. And Woodcock herself has drawn criticism not only from Stupak, but also from Rep. Joe Barton, a Texas Republican, who alleged that she failed to disclose some meetings with industry reps.
With Commissioner Andy von Eschenbach expected to resign soon, Obama and his team will need to make some decisions soon, too. The WSJ suggests that appointing an interim commissioner would give Obama more time to choose a permanent leader. But given the speed with which Obama has been filling in the blanks on his appointment sheet, he doesn't seem likely to stall with this one.
- read the story in the WSJ
- check out the Health Blog's take
Related Articles:
Kindler: Take politics out of the FDA
Developers: Politics behind slow approval process
Who will take over at the FDA, HHS?
Should Kessler return to FDA?
Paid Research Reports
- Trends in mHealth and Telemedicine
- The Global Aesthetic Dermatology Market Outlook
- Future Directions in Regenerative Medicine
- Pipeline Insight: Insulin Antidiabetics – Novel analogs show promise as alternative delivery methods prove less attractive
- Pipeline Insight: Non-insulin Antidiabetics - Rise of the weight-reducers: Once-weekly GLP-1 agonists and novel SGLT-2 inhibitor
- Forecast Insight: Antidiabetics - Diabetes market growth driven by epidemiological trends and rich pipeline


SHARE
WITH: